Chronic granulomatous dermatosis as a presenting sign of cutaneous T-cell lymphomas

Cucuianu, Andrei; Petrushev, Bobe; Crişan, Dana; Buiga, Rareș; Rosu, Ana-Maria; Dima, Delia; Tomuleasa, Ciprian

doi:10.1684/ejd.2015.2530

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral T-cell lymphomas not otherwise specified (NOS) are a heterogeneous group of lymphomas that do not have well-defined criteria for being able to fit into a particular type of lymphoma [ 1 , 2 , 3 , 4 ]. The incidence of T-cell lymphomas in our center is small, only 8.2%.…”

Section: Introductionmentioning

confidence: 99%

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP

et al. 2020

Self Cite

View full text Add to dashboard Cite

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options.

show abstract